First of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma

Trial Profile

First of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Most Recent Events

    • 24 Aug 2016 According to a Nordic Nanovector media release, optimized dose regimen of Lymrit 37-01 study will be used in PARADIGME study which is planned to start in 2H 2017.
    • 18 Aug 2016 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017 according to a Nordic Nanovector media release.
    • 15 Apr 2016 According to a Nordic Nanovector media release, the pivotal PARADIGME study expected to start in Q1 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top